Lipocine (LPCN) Net Cash Flow (2011 - 2025)
Lipocine's (LPCN) quarterly Net Cash Flow came in at -$2.1 million in Q3 2025, down 18.37% YoY from -$2.6 million in Q3 2024, and down 181.99% on a QoQ basis from $2.6 million in Q2 2025.
Lipocine (LPCN) Net Cash Flow (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Net Cash Flow data on file, last reported at -$2.1 million in Q3 2025.
- Quarterly Net Cash Flow fell 18.37% year-over-year to -$2.1 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$2.4 million (down 265.99% YoY) and the FY2024 annual result came in at $1.4 million, down 11.65% from the prior year.
- Net Cash Flow eased to -$2.1 million in Q3 2025, from $2.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $2.8 million in Q1 2022 to a low of -$8.6 million in Q1 2021.
- A 5-year average of -$1.1 million and a median of -$941989.0 in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2021 — Net Cash Flow sank 617.03% — and 2024, when it surged 906.88%.
- Tracing LPCN's Net Cash Flow over 5 years: stood at -$1.6 million in 2021, then soared by 147.97% to $751536.0 in 2022, then decreased by 6.98% to $699052.0 in 2023, then jumped by 252.33% to $2.5 million in 2024, then sank by 187.01% to -$2.1 million in 2025.
- The last three Net Cash Flow figures came in at -$2.1 million (Q3 2025), $2.6 million (Q2 2025), and -$2.9 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.14 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | 2.61 Mn |
| Mar 31, 2025 | -2.85 Mn |
| Mar 31, 2025 | -2.85 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | -1.81 Mn |
| Sep 30, 2024 | -1.81 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | -1.69 Mn |
| Mar 31, 2024 | -1.69 Mn |
| Dec 31, 2023 | 699,052.00 |
| Dec 31, 2023 | 699,052.00 |
| Sep 30, 2023 | -941,989.00 |
| Sep 30, 2023 | -941,989.00 |
| Jun 30, 2023 | 245,515.00 |
| Jun 30, 2023 | 245,515.00 |